Page 7 - Junshi Bioscience News Today

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors --Toripalimab continues to demonstrate synergy as the

Investegate announcements from Junshi Biosciences, Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Investegate announcements from Junshi Biosciences, VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint --VV116 has a favorable safety profile and...

--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint --VV116 has a favorable safety profile and fewer adverse events than PAXLOVID SHANGHAI

(Reuters) - More Shanghai residents were given the freedom to go out to shop for groceries for the first time in nearly two months on Thursday as auth...

BEIJING (Reuters) - An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early pro...

--5th approved indication by NMPA significantly expands eligible patient population...

The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.